id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0502-0006,FDA,FDA-2025-E-0502,Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT,Notice,Determinations,2026-04-16T04:00:00Z,2026,4,2026-04-16T04:00:00Z,2026-06-16T03:59:59Z,2026-04-16T17:53:26Z,2026-07422,1,0,09000064b9286364
FDA-2025-E-0502-0005,FDA,FDA-2025-E-0502,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2026-03-18T04:00:00Z,2026,3,2026-03-18T04:00:00Z,,2026-03-19T00:18:19Z,,0,0,09000064b9222e54
FDA-2025-E-0502-0004,FDA,FDA-2025-E-0502,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-12-18T05:00:00Z,2025,12,2025-12-18T05:00:00Z,,2025-12-19T02:31:26Z,,0,0,09000064b90f02b2
FDA-2025-E-0502-0003,FDA,FDA-2025-E-0502,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-10-10T04:00:00Z,2025,10,2025-10-10T04:00:00Z,,2025-12-18T21:59:33Z,,0,0,09000064b900704e
FDA-2025-E-0502-0002,FDA,FDA-2025-E-0502,"Patent Extension Application from Foley & Lardner LLP (on behalf of Checkpoint Therapeutics, Inc.)",Other,Application,2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:45:37Z,,0,0,09000064869951c4
FDA-2025-E-0502-0001,FDA,FDA-2025-E-0502,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:44:20Z,,0,0,09000064869951c2